Cormedix To Participate In Upcoming Investor Conferences

2025-08-28 08:31:32

(MENAFN- GlobeNewsWire - Nasdaq) BERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in September.

Cantor Global Healthcare Conference

Date:	September 5, 2025
Time:	8:35am Eastern
Format:	Fireside Chat
Webcast:	Link to webcast

Morgan Stanley 23 ^rd Annual Global Healthcare Conference

Date:	September 10, 2025
Time:	10:45am Eastern
Format:	Fireside Chat
Webcast:	Link to webcast

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath^® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath^® in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix commenced clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath^® as a catheter lock solution for use in other patient populations. For more information visit: .

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
...
(617) 430-7576

MENAFN28082025004107003653ID1109988490

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.